Evidence map›Paper›PMID 22367731›Full record

GuidelineMenopause (New York, N.Y.)2012

The 2012 hormone therapy position statement of: The North American Menopause Society.

North American Menopause Society

Registry-linked trialOpen access · greenAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Menopause (New York, N.Y.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02710214 (Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS), which is not on this map. Cited by 160 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 13 pooled it
65.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02710214 phase2completednot on this mapstarted 2016, after this paper: background citation

Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2019Enrolled24ConditionsMenopause, Multiple SclerosisArmsTissue Selective Estrogen Complex, Placebo
3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 13 syntheses or guidelines pooled it, 779 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Bioidentical hormones for women with vasomotor symptoms.The Cochrane database of systematic reviews · 2016
    Pooled it
  10. Exercise for vasomotor menopausal symptoms.The Cochrane database of systematic reviews · 2014
    Pooled it
  11. Pooled it
  12. Phytoestrogens for menopausal vasomotor symptoms.The Cochrane database of systematic reviews · 2013
    Pooled it
  13. Acupuncture for menopausal hot flushes.The Cochrane database of systematic reviews · 2013
    Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

North American Menopause Society
North American Menopause Society · US

Funding

Psychobiology and Treatment of Perimenopausal Mood DisordersZIAMH002537 · NATIONAL INSTITUTE OF MENTAL HEALTH · 2025 to 2025
$1.4M
PSYCHOBIOLOGY AND TREATMENT OF PERIMENOPAUSAL MOOD DISORDERSZ01MH002537 · NATIONAL INSTITUTE OF MENTAL HEALTH · 1990 to 2005
–
Intramural NIH HHS Z01 MH002537
6 · The paper itself

Abstract

objectiveThis position statement aimed to update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2010 regarding recommendations for hormone therapy (HT) for postmenopausal women. This updated position statement further distinguishes the emerging differences in the therapeutic benefit-risk ratio between estrogen therapy (ET) and combined estrogen-progestogen therapy (EPT) at various ages and time intervals since menopause onset.

methodsAn Advisory Panel of expert clinicians and researchers in the field of women's health was enlisted to review the 2010 NAMS position statement, evaluate new evidence, and reach consensus on recommendations. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement.

resultsCurrent evidence supports the use of HT for perimenopausal and postmenopausal women when the balance of potential benefits and risks is favorable for the individual woman. This position statement reviews the effects of ET and EPT on many aspects of women's health and recognizes the greater safety profile associated with ET.

conclusionsRecent data support the initiation of HT around the time of menopause to treat menopause-related symptoms and to prevent osteoporosis in women at high risk of fracture. The more favorable benefit-risk ratio for ET allows more flexibility in extending the duration of use compared with EPT, where the earlier appearance of increased breast cancer risk precludes a recommendation for use beyond 3 to 5 years.

Indexed as

Breast NeoplasmsCarcinomaEstrogensFemaleFractures, BoneHormone Replacement TherapyHumansOsteoporosisPerimenopausePostmenopauseProgestinsRiskEstrogensProgestins

Identifiers

PMID22367731
PMCPMC3443956
OpenAlexW2112457093

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.